Chemomab (CMMB) Enterprise Value to EBITDA Ratio

Public company logo of Chemomab Therapeutics Ltd. (CMMB)

Chemomab Therapeutics (CMMB) develops monoclonal antibodies to treat fibrous inflammation, ensuring high profitability through extended patent lifespans. This price chart, which serves as confirmation of the market valuation, is based on the monetization of unique formulas where a lack of analogues guarantees a stable income of 0.00. The business's resilience to external crises relies on the demand for innovation and the success of clinical trials.

Chemomab Therapeutics Ltd. - CMMB Company Value to EBITDA (period 11/23/2025 - 11/14/2026)

Comprehensive metric breakdowns and analytics for chemomab.com (CMMB)

- current price and projected stock value:
Stock Price Chemomab Therapeutics Ltd.|CMMB - Analyst Median Target
- market capitalization details:
Market Valuation CMMB|CMMB - Full Business Value
- business book valuation details:
Book Value per Share Chemomab Therapeutics|CMMB - Total Stockholders' Equity|Market Capitalization to Book Value Ratio chemomab.com|CMMB - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Chemomab Therapeutics|CMMB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Chemomab Therapeutics Ltd.|CMMB - Company Aggregate Indebtedness|Debts to Book Capitalization CMMB|CMMB - Company Long-Term Loans and Borrowings|Company Short-Term Debts Chemomab Therapeutics|Quick Liquidity chemomab.com
- financial results and valuation multiples details:
CMMB - Final Profit|Expected Profit Chemomab Therapeutics|CMMB - Price to Earnings Ratio|Forward P/E Multiple Chemomab Therapeutics Ltd.|CMMB - PEG Multiple|EV/EBITDA Multiple CMMB|CMMB - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Chemomab Therapeutics|CMMB - Earnings per share for the trailing year|Quarterly EPS earnings growth chemomab.com|CMMB - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Chemomab Therapeutics
- revenue and sales details:
CMMB - Company Sales|Company Projected Revenue Chemomab Therapeutics Ltd.|CMMB - Price to Sales|Price-to-Projected Revenue Ratio CMMB
Fundamental valuation:Chemomab CMMB
Manufactured products of Chemomab Therapeutics Ltd.

For the science-driven Chemomab Therapeutics (CMMB), which invests in biologists and RSU, fluctuations in the EV/EBITDA multiple reflect the balance between the enterprise value and its operational efficiency. This indicator compares total market capitalization with pre-tax profit, allowing investors to assess the real value of assets stripped of tax distortions and to promptly identify speculative overheating of quotes.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Kamada Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Corp)|ABEO: EV/EBITDA Multiple|Mereo BioPharma Group plc (MREO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc.|PLRX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied Therapeutics (APLT)|Enterprise Value to EBITDA Ratio Aileron Therapeutics RNTX|EV/EBITDA Multiple GELS (Gelteq)|EV/EBITDA Multiple Aytu BioPharma Inc AYTU|SRx Health - EV/EBITDA Multiple|Polyrizon Ltd (PLRZ) - Enterprise Value to EBITDA Ratio|AEZS: EV/EBITDA Multiple|Cyclo Therapeutics, Inc - Business Value to Operating Income Before Depreciation|INZY (Inozyme Pharma Inc.) - EV/EBITDA Multiple|Company Value to EBITDA reneopharma.com RPHM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization COSCIENS Biopharma (CSCI)